iCAD (NASDAQ:ICAD) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of iCAD (NASDAQ:ICAD) in a research note issued to investors on Monday morning. The firm issued a sell rating on the technology company’s stock.

Several other equities analysts have also recently commented on ICAD. Laidlaw reaffirmed a “hold” rating on shares of iCAD in a research note on Thursday, April 17th. Craig Hallum cut shares of iCAD from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 16th. Finally, BTIG Research cut shares of iCAD from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 16th.

iCAD Trading Down 0.5%

Shares of NASDAQ:ICAD opened at $3.91 on Monday. The company has a 50 day moving average of $2.58 and a 200 day moving average of $2.35. The stock has a market cap of $107.31 million, a P/E ratio of -30.08 and a beta of 1.35. iCAD has a 12 month low of $1.18 and a 12 month high of $4.00.

iCAD (NASDAQ:ICAD) last issued its quarterly earnings data on Tuesday, May 13th. The technology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.04. The company had revenue of $4.87 million during the quarter, compared to analysts’ expectations of $4.54 million. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%.

Institutional Investors Weigh In On iCAD

Hedge funds have recently made changes to their positions in the business. waypoint wealth counsel boosted its position in iCAD by 44.0% during the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock valued at $26,000 after buying an additional 4,400 shares during the period. Thompson Davis & CO. Inc. purchased a new stake in iCAD during the 4th quarter valued at $31,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in iCAD during the 1st quarter valued at $40,000. PKS Advisory Services LLC purchased a new stake in iCAD during the 4th quarter valued at $53,000. Finally, Wells Fargo & Company MN boosted its position in iCAD by 51.3% during the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock valued at $72,000 after buying an additional 13,402 shares during the period. 24.61% of the stock is currently owned by institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.